Allogene Therapeutics
Jay Cuenca is a seasoned professional with extensive experience in the biopharmaceutical industry. Currently serving as Senior Director of Manufacturing at Allogene Therapeutics since December 2019, Jay previously held various significant roles at Boehringer Ingelheim, including Senior Associate Director of Cell Culture Manufacturing Operations. Prior positions include senior scientist roles at AbbVie and Abbott Biotherapeutics Corporation, along with earlier development engineering and research associate positions at Facet Biotech, PDL BioPharma, and Chromatin, Inc. Jay holds a Master's degree in Biotechnology and a Bachelor of Arts in Biochemistry, Molecular and Cell Biology from Northwestern University.
This person is not in any teams
Allogene Therapeutics
1 followers
Allogene Therapeutics is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. The goal of our allogeneic cell therapy platform is simple: take the same biological processes that allow the first generation autologous CAR T therapies to deliver breakthrough clinical benefits but eliminate the need to create a personalized therapy for each patient. Instead, we start with T cells from healthy donors, which is intended to allow for creation of inventory for “off-the-shelf” use in patients faster, more reliably, and at greater scale.